Literature DB >> 6187038

Kinetics of l-5-hydroxytryptophan in healthy subjects.

H G Westenberg, T W Gerritsen, B A Meijer, H M van Praag.   

Abstract

The kinetics of l-5-hydroxytryptophan (5-HTP) were studied in five volunteers after intravenous and oral administration of 5-HTP following pretreatment with carbidopa. In addition, the effect of pretreatment with carbidopa on metabolism and disposition of 5-HTP was studied in eight subjects. The kinetics of 5-HTP following a 20-minute linear infusion are adequately described by a biexponential function. The biological half-life of 5-HTP ranged from 2.2 to 7.4 hours, and the plasma clearance ranged from 0.10 to 0.23 1/kg/hour. The bioavailability of 5-HTP after oral administration in combination with carbidopa was calculated as 48% +/- 15 (mean +/- SD). The plasma concentrations of 5-HTP observed in this study displayed an unusual double peak in most subjects after oral administration. Pretreatment with carbidopa caused a significant increase in the extent of absorption of unchanged 5-HTP, and a significant reduction in the area under the plasma concentration-time curves of 5-hydroxyindoleacetic acid. Gastrointestinal side effects appeared to be related to the 5-HTP plasma concentration.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6187038     DOI: 10.1016/0165-1781(82)90074-9

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  9 in total

1.  Serotonergic Modulation Enables Pathway-Specific Plasticity in a Developing Sensory Circuit in Drosophila.

Authors:  Takuya Kaneko; Ann Marie Macara; Ruonan Li; Yujia Hu; Kenichi Iwasaki; Zane Dunnings; Ethan Firestone; Shawn Horvatic; Ananya Guntur; Orie T Shafer; Chung-Hui Yang; Jie Zhou; Bing Ye
Journal:  Neuron       Date:  2017-07-14       Impact factor: 17.173

2.  Blood and urine 5-hydroxytryptophan and 5-hydroxytryptamine levels after administration of two 5-hydroxytryptamine precursors in normal man.

Authors:  T C Wa; N J Burns; B C Williams; S Freestone; M R Lee
Journal:  Br J Clin Pharmacol       Date:  1995-03       Impact factor: 4.335

3.  Increase of urinary 5-hydroxyindoleacetic acid excretion but not serum chromogranin A following over-the-counter 5-hydroxytryptophan intake.

Authors:  Tisha Joy; Grace Walsh; Sonya Tokmakejian; Stan Hm Van Uum
Journal:  Can J Gastroenterol       Date:  2008-01       Impact factor: 3.522

4.  Insensitivity of NMRI mice to selective serotonin reuptake inhibitors in the tail suspension test can be reversed by co-treatment with 5-hydroxytryptophan.

Authors:  Jacob P R Jacobsen; Elsebet Ø Nielsen; Rene Hummel; John Paul Redrobe; Naheed Mirza; Pia Weikop
Journal:  Psychopharmacology (Berl)       Date:  2008-05-22       Impact factor: 4.530

5.  Serotonergic function and late luteal phase dysphoric disorder.

Authors:  A T Veeninga; H G Westenberg
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

6.  The effects of 5-hydroxytryptophan on attention and central serotonin neurochemistry in the rhesus macaque.

Authors:  Hannah Weinberg-Wolf; Nicholas A Fagan; George M Anderson; Marios Tringides; Olga Dal Monte; Steve W C Chang
Journal:  Neuropsychopharmacology       Date:  2018-01-30       Impact factor: 7.853

7.  Tryptophan-enriched diet or 5-hydroxytryptophan supplementation given in a randomized controlled trial impacts social cognition on a neural and behavioral level.

Authors:  V Zamoscik; S N L Schmidt; R Bravo; L Ugartemendia; T Plieger; A B Rodríguez; M Reuter; P Kirsch
Journal:  Sci Rep       Date:  2021-11-04       Impact factor: 4.379

8.  The serotonergic system: its role in pathogenesis and early developmental treatment of autism.

Authors:  D I Zafeiriou; A Ververi; E Vargiami
Journal:  Curr Neuropharmacol       Date:  2009-06       Impact factor: 7.363

9.  Serotonin concentration enhancers at clinically relevant doses reduce [11C]AZ10419369 binding to the 5-HT1B receptors in the nonhuman primate brain.

Authors:  Kai-Chun Yang; Akihiro Takano; Christer Halldin; Lars Farde; Sjoerd J Finnema
Journal:  Transl Psychiatry       Date:  2018-07-16       Impact factor: 6.222

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.